Bausch Health Companies Inc. (TSX: BHC)
Market Cap | 4.06B |
Revenue (ttm) | 12.80B |
Net Income (ttm) | -240.47M |
Shares Out | n/a |
EPS (ttm) | -0.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 41,101 |
Open | 10.91 |
Previous Close | 11.05 |
Day's Range | 10.78 - 10.98 |
52-Week Range | 5.45 - 15.43 |
Beta | 0.77 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 20, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in... [Read more]
Financial Performance
In 2023, Bausch Health Companies's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 163.1% more than in 2022.
Financial numbers in USD Financial StatementsNews
Contact lens maker Bausch + Lomb says it is exploring sale
Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.
Bausch & Lomb edges higher after confirming sales process
Bausch & Lomb (BLCO) confirms sales process for eyecare company, exploring potential sale options as part of full separation from Bausch Health Companies...
Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors
Bausch Health Companies Inc (BHC) Responds to Potential Sale Rumors
Bausch + Lomb Responds to Rumors of a Potential Sale
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement...
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a...
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday.
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affili...
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
Analysis of Bausch + Lomb Corporation's debt issues, Bausch Health Companies Inc.'s Q3 results, and strategies to overcome issues. Click for more on BLCO and BHC.
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation...
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
We are bullish on undervalued Bausch Health Companies (BHC) for 2024 and beyond, citing spin-off benefits, innovation, and market expansion. See more here.
Bausch Health names Jonathan Sadeh as chief medical officer
Bausch Health Appoints New Chief Medical Officer and Head of R&D
LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medi...
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)...
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and ben...
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...
Bausch Health Companies Inc. 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Bausch Health Companies Inc.
Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Transcript
Bausch Health raises 2024 revenue guidance
Bausch Health Announces Third Quarter 2024 Results
Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1 Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic...
Bausch + Lomb Announces Third-Quarter 2024 Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quar...
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterolog...
Bausch rejects latest bondholder debt proposals - WSJ
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb BLCO, the Financial Times reported.
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. ...